Stocks
ABIOMED Financial Statements (ABMD) |
||||||||||
| ABIOMEDsmart-lab.ru | % | 2022Q3 | 2022Q4 | 2022Q4 | 2023Q1 | 2023Q2 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.02.2022 | 31.03.2022 | 20.05.2022 | 04.08.2022 | 03.11.2022 | 03.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 261.2 | 269.9 | 269.9 | 277.1 | 265.9 | 1 083 | |||
| Operating Income, bln rub | 64.6 | 65.0 | 65.0 | 66.1 | 58.0 | 254.1 | ||||
| EBITDA, bln rub | ? | 71.6 | 74.8 | 75.2 | 72.7 | 64.7 | 287.4 | |||
| Net profit, bln rub | ? | 45.8 | 60.3 | 60.3 | 54.6 | 106.1 | 281.3 | |||
| OCF, bln rub | ? | 90.5 | 79.0 | 68.1 | 13.4 | 160.5 | ||||
| CAPEX, bln rub | ? | 6.48 | 14.9 | 6.78 | 5.61 | 27.3 | ||||
| FCF, bln rub | ? | 84.0 | 64.1 | 61.3 | 7.81 | 133.2 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 148.5 | 153.4 | 153.4 | 158.5 | 159.0 | 624.3 | ||||
| Cost of production, bln rub | 47.6 | 51.5 | 51.5 | 52.6 | 48.9 | 204.4 | ||||
| R&D, bln rub | 40.9 | 43.8 | 43.8 | 40.5 | 42.1 | 170.1 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 9.76 | 3.77 | 80.7 | 94.2 | ||||
| Assets, bln rub | 1 593 | 1 673 | 1 673 | 1 704 | 1 697 | 1 697 | ||||
| Net Assets, bln rub | ? | 1 433 | 1 503 | 1 503 | 1 536 | 1 540 | 1 540 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Cash, bln rub | 669.2 | 758.6 | 758.6 | 844.3 | 820.4 | 820.4 | ||||
| Net debt, bln rub | -669.2 | -758.6 | -758.6 | -844.3 | -820.4 | -820.4 | ||||
| Ordinary share price, rub | 359.2 | 331.2 | 331.2 | 247.5 | 245.7 | 377.5 | ||||
| Number of ordinary shares, mln | 45.5 | 45.5 | 45.5 | 45.6 | 45.4 | 45.4 | ||||
| Market cap, bln rub | 16 345 | 15 074 | 15 079 | 11 280 | 11 146 | 17 126 | ||||
| EV, bln rub | ? | 15 676 | 14 315 | 14 321 | 10 436 | 10 326 | 16 306 | |||
| Book value, bln rub | 1 309 | 1 387 | 1 381 | 1 413 | 1 417 | 1 417 | ||||
| EPS, rub | ? | 1.01 | 1.33 | 1.33 | 1.20 | 2.34 | 6.20 | |||
| FCF/share, rub | 1.85 | 0.00 | 1.41 | 1.35 | 0.17 | 2.94 | ||||
| BV/share, rub | 28.8 | 30.5 | 30.3 | 31.0 | 31.2 | 31.2 | ||||
| EBITDA margin, % | ? | 27.4% | 27.7% | 27.9% | 26.2% | 24.3% | 26.5% | |||
| Net margin, % | ? | 17.5% | 22.4% | 22.4% | 19.7% | 39.9% | 26.0% | |||
| FCF yield, % | ? | 1.14% | 0.91% | 1.34% | 1.86% | 1.95% | 0.78% | |||
| ROE, % | ? | 8.51% | 13.9% | 13.9% | 13.4% | 20.3% | 18.3% | |||
| ROA, % | ? | 7.65% | 12.5% | 12.5% | 12.1% | 18.4% | 16.6% | |||
| P/E | ? | 134.1 | 72.2 | 72.2 | 54.7 | 35.7 | 60.9 | |||
| P/FCF | 88.1 | 74.9 | 53.9 | 51.3 | 128.6 | |||||
| P/S | ? | 16.0 | 14.5 | 14.5 | 10.5 | 8.35 | 15.8 | |||
| P/BV | ? | 12.5 | 10.9 | 10.9 | 7.98 | 7.87 | 12.1 | |||
| EV/EBITDA | ? | 78.2 | 51.4 | 51.5 | 36.7 | 29.6 | 56.7 | |||
| Debt/EBITDA | -3.34 | -2.72 | -2.73 | -2.97 | -2.35 | -2.85 | ||||
| R&D/CAPEX, % | 630.9% | 294.0% | 596.7% | 750.4% | 623.6% | |||||
| CAPEX/Revenue, % | 2.48% | 0.00% | 5.52% | 2.45% | 2.11% | 2.52% | ||||
| ABIOMED shareholders | ||||||||||
